Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-cell receptors (TCRs) recognizing poliovirus-derived peptides presented on MHC class II molecules are specialized protein complexes found on the surface of CD4+ T helper cells. These receptors play a pivotal role in the adaptive immune response by identifying specific viral fragments, typically from the poliovirus capsid proteins VP1, VP2, VP3, and VP4, that are displayed by antigen-presenting cells (PMID: 28416511). Upon binding to the peptide-MHC II complex, the TCR initiates intracellular signaling that leads to T-cell activation, proliferation, and the secretion of pro-inflammatory cytokines such as interferon-gamma (PMID: 16148104). This process is essential for providing help to B cells for high-affinity neutralizing antibody production and for establishing long-lived memory T cells. These TCRs are the primary cellular targets of poliovirus vaccines, including the Inactivated Poliovirus Vaccine (IPV) and the Oral Poliovirus Vaccine (OPV), which aim to elicit a robust and specific T-cell repertoire (PMID: 30206155). Understanding the diversity and specificity of these TCRs is crucial for monitoring vaccine-induced immunity and for the development of new vaccine strategies to combat vaccine-derived poliovirus outbreaks. Furthermore, these receptors serve as key indicators in research focusing on the cellular correlates of protection against poliomyelitis. Therapeutic challenges include the potential for viral mutations to escape TCR recognition and the need for broad MHC coverage across diverse human populations.
Vaccine-derived poliovirus peptides are processed and presented by MHC class II molecules on antigen-presenting cells to these specific T-cell receptors, inducing CD4+ T-cell activation, cytokine release, and the establishment of immunological memory.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor recognizing poliovirus-derived peptides presented on MHC class II (Poliovirus-specific TCR (MHC-II restricted)).